A news release from Biomerica reveals that its EZ Detect colon disease screening test is going to be available for purchase at Walmart. This is an at-home test that allows users to detect hidden blood in their stool. This can be an early sign of colorectal diseases such as colon and rectal cancers.
That’s worth noting as colorectal cancer is the second most common cause of cancer death in the U.S. An estimated 147,950 were diagnosed with it in 2020 with an estimated 53,200 would die from it.
The first shipment of EZ Detect has been sent out to Walmart. The two companies are still finalizing the last bits of the deal so they can show up on store shelves. To go along with that, Biomerica is working to release the product in Asia, Europe, and the Middle East.
Zack Irani, CEO of Biomerica, had this to say in the press release boosting BMRA stock today.
“With the current COVID-19 pandemic, consumers have become much more aware of at-home diagnostic testing and are more comfortable performing these tests. For this reason, many global retailers are expanding their focus on selling home health solutions. This growing trend presents many opportunities for our EZ Detect™ colorectal disease test, our Aware™ breast self-exam product and other products that we make for in-home use.”
BMRA stock was up 26.7% as of Friday morning.
There’s more stick market news to jump into below!
We’ve got all the latest stock stories that traders need to know about today. That includes the latest concerning Dogecoin (CCC:DOGE-USD), Merck (NYSE:MRK), and this morning’s pre-market stock movers. You can get all those details at the following links!
More Friday Stock Market News
- Are NFTs Coming to Dogecoin? 9 Things to Know About the Big Vision Lifting DOGE Today.
- Merck News: The ‘Game-Changer’ Making MRK Stock the No. 1 Trending Ticker Today
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed